Just recently posted, recorded at the Gstaad Longevity investor Conference: https://www.longevityinvestors.ch
7 Likes
I watched the video and followed a link to a site with an article by Kennedy. Apparently he is working with the government of Singapore. First they will be testing exercise and some supplement interventions. But, he hopes to be testing rapamycin on people soon. It would be great if some large scale tests with people are done soon.
The article is here
6 Likes
Yes - I spoke with Max Unfried who works in his Lab (based in Singapore) at the recent San Francisco Longevity meetup. Max thought that the rapamycin study that Brian Kennedy is doing will be starting in early 2023, will consist of about 80 people, and will be 6 months long (they are looking at a large battery of biomarkers and blood tests to look for physiological improvements).
If results are as positive as I expect, I suppose that then there would be larger trials to follow.
4 Likes
New interview with Brian Kennedy:
One thing he mentions is that he, personally, takes sub-lingual NAD, and he says it raises NAD levels in blood. Whether it also raises it in cells is yet to be determined.
Addendum: Oh, one other thing he did say was that he now uses a lot of language model AIs in his work. 1 hour, 1 minute in he says:
I never thought I would say this… half my lab is AI now. So, we’re doing a lot of drug screening – sort of in silico – looking at large language models and interrogating [for] drugs that might affect longevity. We’re doing that with peptides now.
5 Likes
New paper that includes Brian Kennedy:
https://onlinelibrary.wiley.com/doi/10.1111/acel.70517
Supplements and Drugs Are Associated With Biological Age in a Cohort of Exceptionally Healthy Individuals
Further down in the paper they mention some interesting results for CoQ10:
CoQ10 is a lipid-soluble antioxidant and mitochondrial electron carrier. We found that CoQ10 use at baseline was associated with significantly better odds of reduced biological age at follow-up, even though CoQ10 was not beneficial in the cross-sectional analysis. This result certainly merits follow-up given the multifaceted role of CoQ10 in longevity. CoQ10 levels decline with aging in mouse and human tissues (Kalén et al. [1989]) and, based on this, multiple groups tested whether CoQ10 supplementation can extend the lifespan of rats and mice, generally with negative results (Sohal et al. [2006]); Lönnrot et al. [1998]). In humans, on the other hand, CoQ10 has been found to improve cardiometabolic risk factors (Liu et al. [2022]) and decrease mortality in heart failure patients (Xu et al. [2024]).
2 Likes
Very annoying that it didn’t mention which form of Coq10 was used. Also didn’t mention which antihistamines were most beneficial. Or did I miss that?
In a longitudinal subset, intake of coenzyme Q10 (CoQ10) and dAKG was associated with increased odds of a lower Age Residual, but the results were not significant after multivariate correction.
Not impressive.